Aripiprazole Augmentation in Treatment-Resistant Depression

References

• Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996; 19(2):179–200.
   PubMed Web of Science ®Google Scholar
• Sackheim HA. The defmition and meaning of treat-ment-resistant depression. J Clin Psychiatry 2001; 62 (suppl 16):10–17.
   Google Scholar
• Fawcett J. Antidepressants: Partial response in chronic depression. Br J Psychiatry Suppl 1994 (Dec); (26): 37–41.
   Google Scholar
• Rush AJ, Trivedi MIL Treating depression to remis-sion. Psych Annals 1995; 25(12):704–709.
   Google Scholar
• Shelton RC, Tollefson GD, Tohen M, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158:131–134.
   PubMed Web of Science ®Google Scholar
• Rappaport M, Gharabawi G, Canuso C, et al. Prelim-inary results from ARISe-RD (risperidone augmentation in resistant depression) trial. Presented at the 43rd Annual NCDEU Meeting May 2003.
   Google Scholar
• Papakostas GI, Petersen TJ, Nierenberg AA, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-Resistant Major Depressive Disorder. J Clin Psychiatry 2004; 65(3):217–221.
   Google Scholar
• Hirose S, Ashby CR. An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy. J Clin Psych 2002; 63(8):733–736.
   Google Scholar
• Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depres-sion. J Clin Psych 1999; 60(4):256–259.
   Google Scholar
• Marangell LB, Johnson CR, Kertz B, et al. Olanzapine in the treatment of apathy in previously depressed par-ticipants maintained with selective serotonin reuptake inhibitors: An open-label, flexible-dose study. J Clin Psych 2002; 63:391–395.
   Google Scholar
• Viner MW, Chen Y, Bakshi I, et al. Low-dose risperi-done augmentation of antidepressants in nonpsychotic depressive disorders with suicidal ideation. J Clin Psy-chopharmacol 2003; 23(1):104–106.
   Google Scholar
• O'Connor M, Silver H. Adding risperidone to selective serotonin reuptake inhibitor improves chronic depres-sion. J Clin Psychopharmacol 1998; 18(1):89–91.
   Google Scholar
• Stoll AL, Haura G. Tranylcypromine plus risperidone for treatment-refractory major depression. J Clin Psy-chopharmacol 2000; 20(4):495–496.
   Google Scholar
• Pitchot W, Ansseau M. Addition of olanzapine for treatment-resistant depression. Am J Psychiatry 2001; 158(10):1737–1738.
   Google Scholar
• Jordan S, Koprivica V. Chen R, et al. The antipsy-chotic aripiprazole is a potent, partial agonist at the human 5HTIA receptor. Eur J Pharmacol 2002; 441:137–140.
   PubMed Web of Science ®Google Scholar
• Lawler CP, Prileau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsy-chopharmacology 1999; 20(6):612–627.
   PubMed Web of Science ®Google Scholar
• Blier P, Ward NM. Is there a role for 5HT IA agonists in the treatment of depression. Biol Psychiatry 2003; 53:193–203.
   PubMed Web of Science ®Google Scholar
• Ruwe F, Gibertini M. Relapse prevention with gepirone-ER in outpatients with major depression. Pre-sented at the 43rd Annual NCDEU Meeting 2003.
   Google Scholar
• Lavretsky H, Kumar A. Methylphenidate augmentation of citalopram in elderly depressed patients. Am J Geri-atric Psych 2001; 9(3):298–303.
   Google Scholar
• Ostow M. Pramipexole for depression. Am J Psychiatry 2002; 159(2):320–321.
   PubMedGoogle Scholar
• Lattanzi L, Dell'Osso L, Cassano P. et al. Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord 2002; 4:307–314.
   Google Scholar
• Guy W. Clinical global impressions. ECDEU Assess-ment Manual for Psychopharmacology. US Dept Health, Education and Welfare publication (ADM) 76–338. Rockville, MD: National Institute of Mental Health; 1976:218–222.
   Google Scholar
• Endicott J, Spitzer RL, Fleiss JL, et al. The global assessment of functioning scale: A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1976; 33(6):766–771.
   PubMed Web of Science ®Google Scholar
• Thase ME, Rush AJ. When at first you don't succeed: Sequential strategies for antidepressant nonresponders. J Clin Psychiatry 1997; 58\(suppl 13):23–29.
   Google Scholar
• Barbee JG. Mixed symptoms and syndromes of anxiety and depression: Diagnostic, prognostic and etiologic issues. Annals Clin Psychiatry 1998; 10(1):15–29.
   Google Scholar
• Bristol Myers Squibb Company and Otsuka Pharma-ceutical, Inc. AbilifyTM package insert. 2003.
   Google Scholar
• Angrist BM, Gershon S. The phenomenology of experi-mentally induced amphetamine psychosis: Preliminary observations. Biol Psychiatry 1970; 2:95–107.
   PubMedGoogle Scholar
• Ellinwood EH. Amphetamine psychosis. I. Description of the individuals and process. J Nerv Mental Dis 1967; 144:273–283.
   Web of Science ®Google Scholar
• Post RM. Cocaine psychosis: A continuum model. Am J Psychiatry 1975; 132:225–231.
   Google Scholar
• Kalivas PW, Pierce RC, Cornish J, et al. A role for sen-sitization in craving and relapse in cocaine addiction. J Psychopharmacol 1998; 12:49–53.
   PubMed Web of Science ®Google Scholar
• Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev 1993; 18:247–291.
   PubMed Web of Science ®Google Scholar
• Pierce RC and Kalivas PW. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res Rev 1997; 25:192–216.
   Google Scholar
• Steketee JD. Neurotransmitter systems of the medial prefrontal cortex: Potential role in sensitization to psy-cho stimulants . Brain Res Rev 2003; 41:203–228.
   PubMed Web of Science ®Google Scholar
• Yoneda Y, Han D, Ogita K. Preferential induction by stress of the N-methyl-D-aspartate recognition domain in discrete structures of rat brain. J Neurochem 1994; 63:1863–1871.
   Google Scholar
• Meller E, Goldstein M, Bohmaker K. Receptor reserve for 5-hydroxytryptamine1_ mediated inhibition of serotonin synthesis: Possible relationship to anxiolytic properties of 5-hydroxytryptamine1 agonists. Mol Pharmacol 1990; 37:231–237.
   Google Scholar
• Charney DS, Krystal JH, Delgado PL, et al. Serotonin-specific drugs for anxiety and depressive disorders. Annu Rev Med 1990; 41:437–446.
   PubMed Web of Science ®Google Scholar